恒瑞医药(600276.SH)：药品上市许可申请获受理并纳入优先审评程序

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for the new indication application of SHR-A1811, an injection for treating locally advanced or metastatic HER2-positive breast cancer in adults who have previously received one or more anti-HER2 therapies. The application has been included in the priority review process [1] Company Summary - Heng Rui Medicine's subsidiary has made progress in the development of SHR-A1811, which targets a specific patient population with HER2-positive breast cancer [1] - The acceptance of the new indication application signifies a potential expansion of the company's product offerings in the oncology market [1] - The inclusion in the priority review process may expedite the approval timeline, enhancing the company's competitive position in the biopharmaceutical sector [1]